1 results match your criteria: "Cancer Research UK Centre for Cancer The Institute of Cancer Research[Affiliation]"
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Cancer Res
March 2009
Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Centre for Cancer The Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom.
Heat shock protein 90 (HSP90) inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), which is currently in phase II/phase III clinical trials, are promising new anticancer agents. Here, we explored acquired resistance to HSP90 inhibitors in glioblastoma (GB), a primary brain tumor with poor prognosis. GB cells were exposed continuously to increased 17-AAG concentrations.
View Article and Find Full Text PDF